IceCure Medical jumps on U.S. ProSense install base growth after FDA clearance
In this article, you’ll find answers to your questions such as: Why did IceCure Medical shares more than triple in late-morning Nasdaq trading? What is driving the sharp rise in U.S. commercial adoption of the ProSense breast-cancer cryoablation system? How significant is the 70% increase in the U.S. install base since FDA authorization? What risks does the company still face, and what are the next steps for investors to watch?